A retrospective, observational study analysing treatment patterns, resource utilization, and costs of Long-Acting Injectable (LAI) Aripiprazole Lauroxil in schizophrenia
Latest Information Update: 24 Sep 2021
At a glance
- Drugs Aripiprazole lauroxil (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- 24 Sep 2021 New trial record
- 12 Sep 2021 Results published in the CNS Drugs